

Stage II – Critical Elements for Psychoactive Medications

Facility Name: _____ Facility ID: _____ Date: _____
Surveyor Name: _____
Resident Name: _____ Resident ID: _____
Initial Admission Date: _____ Interviewable: Yes No Resident Room: _____
Care Area(s): _____

Use
Use this protocol for a sampled resident who triggers for: <input type="checkbox"/> The use of antipsychotic medications without an indication for use; <input type="checkbox"/> The use of long-acting benzodiazepenes; or <input type="checkbox"/> The use of medications, such as anxiolytics and/or hypnotics. Note: In addition, use if, during the review of other CEs or medication pass observation, the surveyor identifies potential issues related to the use of psychoactive medication use.

Procedure
<input type="checkbox"/> Briefly review the assessment, care plan and orders to identify facility interventions and to guide observations to be made. <input type="checkbox"/> Corroborate observations by interview and record review.

Observations	
<input type="checkbox"/> Briefly review a resident’s assessment and care plan for the therapeutic goals and monitoring plan for the medications. <input type="checkbox"/> Observe the resident’s functioning and behavior over time and various shifts. <input type="checkbox"/> For closed record review , determine whether the interdisciplinary team evaluated the impact of the medications upon the resident. <input type="checkbox"/> In addition, observe for:	Notes:

Stage II – Critical Elements for Psychoactive Medications

Observations	
<ul style="list-style-type: none">▪ Signs of medication side effects such as unsteady gait; tardive dyskensia (involuntary movement of the facial, limbs and trunk muscles);▪ Parkinson like symptoms (shuffling gait, rigid muscles, shaking);▪ Frequent falls;▪ Refusing to eat;▪ Difficulty swallowing;▪ Dry mouth, depression, suicidal ideations, social isolation, blurred vision;▪ Diarrhea, fatigue, insomnia, loss of appetite, weight loss; and▪ Muscle cramps, nausea, and vomiting or other behavioral/symptomatic changes uncharacteristic of the resident.	
For the resident who is on a hypnotic:	
<p>Determine whether staff are implementing sleep hygiene techniques, such as:</p> <ul style="list-style-type: none"><input type="checkbox"/> Limiting caffeine intake;<input type="checkbox"/> Decreasing noise to the extent possible;<input type="checkbox"/> Providing lighting levels to the tolerance of the resident;<input type="checkbox"/> Providing regular bedtime routine; and<input type="checkbox"/> Maximizing daily activities and encouraging socialization.	Notes:

Stage II – Critical Elements for Psychoactive Medications

Observations	
For the resident who is on an antipsychotic and/or anti-anxiety medication:	
Determine whether staff are: <input type="checkbox"/> Observing and monitoring target behaviors, such as pacing, wandering in other resident rooms, disrobing, inappropriate response to verbal communication, displays of violent/aggressive behavior towards staff and/or other residents, or other symptoms identified on the care plan as part of the behavior management program; <input type="checkbox"/> Monitoring for behaviors that cause the resident or others distress; and <input type="checkbox"/> Observe staff interactions with the resident in response to behavior management plan.	Notes:
Resident/Representative Interview	
Interview the resident, family or responsible party as appropriate to identify: <input type="checkbox"/> The resident's/representative's involvement in the development of the care plan, defining the approaches and goals, and whether interventions reflect choices and preferences; <input type="checkbox"/> Awareness and involvement in the development of the medication regime; <input type="checkbox"/> Involvement in the development of a behavior management program; <input type="checkbox"/> Whether the resident/representative was provided information on the risk and benefits of psychoactive medications and has an understanding of this information; and <input type="checkbox"/> If interventions were declined or refused, what the reasons were for the decline and whether alternative approaches were offered.	Notes:

Stage II – Critical Elements for Psychoactive Medications

Staff Interviews	
<p>Determine whether:</p> <ul style="list-style-type: none"><input type="checkbox"/> Nursing assistants and other support staff know what behavioral changes to report; and<input type="checkbox"/> Nurses have a working knowledge and understanding of, and monitor for, the intended effect and potential adverse effects of the psychoactive medication the resident receives.	<p>Notes:</p>

Assessment	
<p>Review the RAI, physician orders, progress notes, history and physical, consultant reports and other appropriate interdisciplinary notes and any other documentation (MARS, TARs) necessary to evaluate the appropriateness of the treatment regime.</p>	
For the resident on antipsychotic and/or anti-anxiety medications:	
<p>Determine whether the assessment includes (but not limited to):</p> <ul style="list-style-type: none"><input type="checkbox"/> Involvement of social services and activities staff in team decisions for non-medication interventions/treatment of the resident;<input type="checkbox"/> Identification of environmental stimuli, infection, delirium, pain, etc. before medication is used;<input type="checkbox"/> A medical justification for its use, such as an Organic Mental Syndrome (dementia, delirium, etc.) and that the behaviors demonstrated by the resident are psychotic in nature, persistent and cause the resident or others distress, including the medical justification for ongoing use of a medication initiated as an emergency measure;<input type="checkbox"/> The identification of:<ul style="list-style-type: none">▪ Risks/benefits of the medication use;	<p>Notes:</p>

Stage II – Critical Elements for Psychoactive Medications

Assessment	
<ul style="list-style-type: none"> ▪ Possible adverse consequences related to the medication, such as hypersensitivity, idiosyncratic response, and/or toxic reaction, or side effects; ▪ An objective for the medication being used; ▪ A baseline of behaviors for which the medication is prescribed; and ▪ Behaviors to be monitored and type of monitoring necessary (socially inappropriate behavior, etc.). <p><input type="checkbox"/> The assessment for gradual dose reductions for antipsychotic agents and other psychotherapeutic medications (except cognitive enhancers and antidepressants), unless clinically contraindicated;</p> <p><input type="checkbox"/> A review of the medication in relation to the age and medical condition of the resident based on manufacturer’s recommendations, and if the manufacturer’s recommended dose is not used, a clinically-based explanation and physician rationale for the dose provided;</p> <p><input type="checkbox"/> The duration for which the medication is to be administered, including an explanation for the reason administration of a medication is extended and assessed for possible complications; and</p> <p><input type="checkbox"/> The identification of duplicative medication therapy (multiple medications for the same indications or the same medication duplicated), and provided an explanation, reason, or physician rationale for the duplication.</p>	
For the resident on sedative/hypnotic medications:	
<p>Determine whether the assessment:</p> <p><input type="checkbox"/> Identified the cause of the insomnia, and the justification for the use of medication;</p> <p><input type="checkbox"/> Considered alternatives to the use of medication, such as a sleep hygiene program;</p>	Notes:

Stage II – Critical Elements for Psychoactive Medications

Assessment	
<p><input type="checkbox"/> Identified the risk and side effects as a result of the use of medication;</p> <p><input type="checkbox"/> Identified the type of clinical monitoring for medication effect;</p> <p><input type="checkbox"/> Identified the duration for which the medication is to be administered; and</p> <p><input type="checkbox"/> Included an explanation for the reason administration of a medication is extended and assessed for possible complications related to extended duration.</p>	
<p>1. Did the assessment identify the justification for use of medications, any risks and side effects as a result of the use of the medications, monitoring mechanisms and/or alternatives to the use of the medications? <input type="checkbox"/> Yes <input type="checkbox"/> No F272</p>	<p>Notes:</p>
<p><i>The comprehensive assessment is not required to be completed until 14 days after admission. For newly admitted residents, before the 14-day assessment is complete, the lack of sufficient assessment and care planning to meet the resident’s needs should be addressed under F281.</i></p> <p><i>Note: The facility may have completed a 5-day assessment for the Medicare beneficiary. Use the 5-day assessment as the comprehensive assessment only if it was completed with the RAPS.</i></p>	

Care Planning	
<p>Review the care plan for specific interventions, measurable objectives, and timetables. Determine whether the care plan:</p> <p><input type="checkbox"/> Lists measurable goals in behavioral terms for use of psychoactive medications;</p> <p><input type="checkbox"/> Identifies non-drug interventions, such as a sleep hygiene program that consist of behavioral interventions (soft lights, music, massage, no caffeine after 4 p.m. and limits naps);</p>	<p>Notes:</p>

Stage II – Critical Elements for Psychoactive Medications

Care Planning

- Identifies medications, doses, and duration for the age and clinical condition of the resident;
- Identifies who is responsible for monitoring medical parameters and for side effects, and how often monitoring is to be done;
- Lists potential troublesome medication side effects listed in the plan of care, and lists non-drug interventions to address medication side effects, such as increased fluids for a drug that causes dry mouth;
- Identifies side effects for antipsychotic medications, such as
 - Tardive dyskinesia, dry mouth, constipation, blurred vision, drowsiness, weight gain, increased risk of obesity, diabetes and high cholesterol, restlessness, stiffness, tremors, and muscle spasms,
 - Extrapyrimal effects such as contraction of the muscles of neck (torticollis), eyes (oculogyric crisis), tongue (which can cause airway obstruction), jaw and other muscle groups, and
 - Neuroleptic malignant syndrome;
- Lists behavioral interventions, including who is to carry them out, and how often;
- Identifies how, and when, dose reductions will be attempted, (if not clinically contraindicated); and
- Identifies behavioral interventions that reflect current standards of practice in conjunction with psychoactive medications.

Stage II – Critical Elements for Psychoactive Medications

Care Planning	
For psychoactive medications used for residents with dementia:	
<input type="checkbox"/> Determine whether the care plan provides for gradual dose reduction, unless clinically contraindicated.	Notes:
For antipsychotic and anti-anxiety medications:	
<input type="checkbox"/> Doses are started at a low level and increased as needed, and if doses are decreased, a slow taper is used.	Notes:
For hypnotic medications:	
<input type="checkbox"/> The medication is prescribed and used on a PRN rather than a routine basis, and if used more than 10 consecutive days, a dose reduction is attempted, unless clinically contraindicated (most sedatives will lose effectiveness after 2 weeks continuous use).	Notes:

Stage II – Critical Elements for Psychoactive Medications

Care Planning	
<p>2. Did the facility develop a care plan that addresses the use of medications to improve resident quality of care and quality of life; prevent adverse effects or side effects, and monitor to determine whether they are providing intended affects?</p> <p style="text-align: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No F279</p>	<p>Notes:</p>
<p><i>The comprehensive care plan does not need to be completed until 7 days after the comprehensive assessment (the assessment completed with the RAPS). Lack of sufficient care planning to meet the needs of a newly admitted resident should be addressed under F281.</i></p> <p><i>Additionally, lack of physician orders for immediate care (until staff can conduct a comprehensive assessment and develop an interdisciplinary care plan) should be addressed under F271.</i></p>	

Care and Services Meet Professional Standards	
<p><input type="checkbox"/> Interviews with Health Care Practitioners and Professionals: Based on your review, determine whether there is evidence of an event or situation that actually or potentially interfered with the intended or desired outcome of medication therapy.</p> <p>Note: The surveyor is not expected to prove that an adverse event was directly caused by a medication related problem (MRP), but rather that there was a failure in the care process.</p> <p><input type="checkbox"/> Evidence of a potential MRP (such as an adverse outcome or decline potentially related to the therapy) may include but not limited to:</p> <ul style="list-style-type: none"> ▪ A change in mental status or increasing lethargy, confusion, agitation, or mood disturbance; ▪ New onset or recurrent dizziness or falling; or ▪ Anorexia or unplanned weight loss. 	<p>Notes:</p>

Stage II – Critical Elements for Psychoactive Medications

Care and Services Meet Professional Standards

Note: The most common MRPs include: medication use with no indication; inadequate effectiveness of medication; ADR; unintended medication interaction; excessively high dose or duration; and medication use without adequate monitoring.

If there is a potential MRP, ask for evidence that the care process was followed, including the identification and assessment for the need, and monitoring during the use of the medication. Investigate whether evidence exists in the record (including the MRR report) that indicates:

- The facility identified, acknowledged, addressed, and continues to monitor, the potential MRP and/or resident response;
- The facility identified the risk(s) involved with the use of the individual medication or combination of medications;
- The facility could explain why the benefit of the medication(s) or dose(s) outweighed the risks of a potential MRP, or dose reduction is contraindicated, or a particular medication is the one of choice for a resident despite its risks (any medication may be appropriate therapy, if there is documentation substantiating the choice and the benefit, e.g., the resident lacks seizure control unless the dose and blood level exceed the usual recommended therapeutic levels, and the facility is actively monitoring for potential MRPs);
- The risk/benefit of the medication use was provided to the resident or representative;
- The pharmacist identified and reported in a timely manner to the attending physician and the DON the potential MRP;
- There has been action based upon the pharmacist's notice, or the decision to not take action is documented with a clinically-based rationale; and

Stage II – Critical Elements for Psychoactive Medications

Care and Services Meet Professional Standards

- The duration for which the medication is to be administered, including an explanation for the reason administration of a medication is to be extended:
- If an explanation is not provided, record the medication, dosage, date ordered, and date the medication should have been reevaluated, if known.
- Interview the physician, pharmacist, clinical nurse, (including medication administration staff, as appropriate) and/or DON, regarding:
 - The potential MRP and the therapeutic effectiveness of the medication regimen;
 - The monitoring that is in place;
 - The process of the MRR (e.g., computer screening or in-facility review and discussion with direct care staff, etc.);
 - Reporting to the practitioner;
 - The practitioner follow-up; and
 - Reevaluations by the team.
- Note: Allow the facility to provide a rationale for the use of medications prescribed outside the information provided in the interpretive guidelines for Tags F329 and F428. The facility may not justify the use of a medication prescribed outside these guidelines solely on the basis of, “The doctor ordered it.” This justification would render the regulations meaningless. The rationale must be based on a clinically valid review of risks and benefits, the resident’s symptoms and responses to treatment, determination of the ongoing need to treat the target symptom(s), potential adverse effects of the medication, and standards of practice.

Stage II – Critical Elements for Psychoactive Medications

Care and Services Meet Professional Standards

Examples of evidence that would support a justification of why a medication is being used outside these Guidelines, but in the best interest of the resident, may include, but are not limited to, the following:

- A physician's note indicating, for example, why the dosage, duration, indication, or monitoring are clinically appropriate, or otherwise demonstrating that the physician has carefully considered relevant issues and the impact on the resident;
- Documentation of a medical or psychiatric consultation or evaluation that supports the physician's judgment that use of a medication outside the Guidelines is in the best interest of the resident;
- Quantitative and qualitative instruments (e.g., Mini-Mental Status Exam, Geriatric Depression Scale or Behavioral Pathology in Alzheimer's Disease rating scale) establishing treatment benefits;
- Physician, nursing, or other health professional documentation indicating that the resident is being monitored for adverse consequences or complications of the medication therapy and that therapy within the Guidelines has been ineffective;
- Documentation confirming that previous attempts at dosage reduction have been unsuccessful;
- Documentation showing that a resident's decline or deterioration is evaluated by the interdisciplinary team and provides evidence that a particular medication, or a particular dose or duration of therapy, is not the cause or a major contributing factor;
- Documentation showing why the resident's age, weight, or other factors would require a unique medication dose or medication duration, indication, or monitoring approach; and

Stage II – Critical Elements for Psychoactive Medications

Care and Services Meet Professional Standards

- Documentation of current literature substantiating the use of the medication in the specific condition being treated which is outside of the regulatory guidelines.

Determine whether:

- The use of the medication is routinely monitored (i.e., therapeutic effects, side effects, and adverse effects) according to manufacturer's specifications or standards of practice;
- Necessary labs, weights, vital signs, etc. are taken and recorded in the clinical record (See drug reference);
- Doses are appropriately titrated up or down for an elderly person, including planned dose reductions (See drug reference);
- The resident has renal or hepatic impairment and that the dose been adjusted (See drug reference); and
- Whether there is an association between the resident's medications(s) and the recently identified symptoms or condition change such as a fall/recurrent falls, decline in ADL's, or decreased sensorium/increased somnolence.

If there is a concern identified regarding MRP, review the performance of the facility in identifying and monitoring medication therapy. Determine whether the consultant pharmacist:

- Conducts a review of the regimen and signed and dated the MRR at least monthly, or more frequently, if indicated by factors, such as abrupt changes in the resident's clinical condition, numerous changes in, or initiation of, a complex medication regimen; and
- Reports any concerns to the prescriber and DON.

Determine whether the facility responded to the concern and the type of action taken.

Stage II – Critical Elements for Psychoactive Medications

Care and Services Meet Professional Standards

Note: A record of the pharmacist's MRR and the report of irregularities might be part of the clinical record or be retained separately. If not part of the active clinical record, request the report(s).

3. Did the facility implement practices that meet professional standards of quality? Yes No F281

Note: If the care plan addressed the risks and identified needs of the resident, but the care plan was not implemented as written, consider F282 for failure to implement the care plan.

Care Plan Revision

- Determine whether the facility evaluated and assessed:
- The effectiveness of the medication therapy;
 - The potential, and monitoring, for adverse consequences of the medication therapy in accord with the nature of the medication and recommended standards of practice; and
 - Any additional or increasing signs or symptoms of deterioration that have been evaluated as related potentially to the medication therapy (e.g., a resident with dementia who is receiving medication(s) with a potential for somnolence and reduced ability to respond is evaluated objectively for adverse medication effect before the declining condition is ascribed to worsening of the dementia).
- Determine whether revisions were made to the care plan based upon the following:
- Outcomes and the continued use of the medication, (clinical indication for the continued use of the medications);

Notes:

Stage II – Critical Elements for Psychoactive Medications

Care Plan Revision	
<ul style="list-style-type: none"> ▪ Side effects occurred, and the resident and/or responsible party were informed of the risk/benefit analysis and involved/allowed to make a decision on treatment; ▪ Identification of adverse effects indicated that the drug dose should be decreased or discontinued; and ▪ When a dose reduction is to be attempted (if a reduction is not clinically contraindicated), and the reduction is planned in a manner that will promote the success of the reduction. <p>Note: Dose reductions should be attempted twice a year for antipsychotics, and every four months for anti-anxiety medication, unless contraindicated.</p>	
<p>4. Did the facility revise the care plan as needed? <input type="checkbox"/> Yes <input type="checkbox"/> No F280</p>	

Provision of Care and Services	
<p>Criteria for Compliance with F329, Unnecessary drugs — The facility is in compliance with F329, if staff have followed the care process prior to prescribing and administering medication, including:</p> <ul style="list-style-type: none"> <input type="checkbox"/> Identifying the medical justification, including defining diagnoses (to the extent possible); <input type="checkbox"/> Weighing the risk benefit of the anticipated medication individually and in combination with the remainder of the medication regimen; <input type="checkbox"/> Eliminating environmental causative factors; <input type="checkbox"/> Using non-medication interventions, when appropriate, prior to, or in conjunction with, medication therapy; <input type="checkbox"/> Identifying and implementing parameters for monitoring for effectiveness and potential, or actual, adverse consequences; and 	<p>Notes:</p>

Stage II – Critical Elements for Psychoactive Medications

Provision of Care and Services	
<p><input type="checkbox"/> Recognizing actual or potential MRPs, evaluating the resident, and modifying the regimen or weighing the risk-benefit, and defining the clinical rationale for continuing the regimen while addressing the negative outcome.</p> <p>If not, the facility did not provide care and services to prevent adverse effects and use only necessary drugs: cite F 329.</p> <p>5. Based on observation, interviews, and record review did the facility provide care to prevent adverse effects and use only necessary antipsychotic, anti-anxiety, and/or hypnotic drugs?</p> <p style="text-align: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No F329</p>	

Concerns with Structure, Process, and/or Outcome Requirements Related to Process of Care	
<p>During the investigation of the use of antipsychotics, anti-anxiety, and/or hypnotic medication use, the surveyor may have identified concerns with additional requirements. The surveyor is cautioned to investigate these related additional requirements before determining whether non-compliance is present. Examples of some of the related requirements that should be considered include the following:</p> <p><input type="checkbox"/> F154 Notice of Rights, and F155 Free Choice — Determine whether the resident was advised of her/his medical condition and was allowed to exercise informed consent about his/her treatment including medications; and has been advised of her/his therapy and condition.</p> <p><input type="checkbox"/> F157, Notification of Changes — Determine whether the physician is notified if the resident had a significant change of condition or has not responded to the medication regimen in accordance with the goals of therapy.</p> <p><input type="checkbox"/> F353, Sufficient Staff — Determine whether the facility has sufficient staff to:</p> <ul style="list-style-type: none"> ▪ Timely administer medications, 	<p>Notes:</p>

Stage II – Critical Elements for Psychoactive Medications

Concerns with Structure, Process, and/or Outcome Requirements Related to Process of Care

- To evaluate the response of the resident to the medications,
- To implement non-pharmacologic interventions when appropriate to avoid use of unnecessary medication, and
- To identify, and respond to, changes in resident condition, which may indicate an MRP.

F385, Physician Supervision — Determine whether the physician supervised the resident's medical treatment, assessing the resident's condition (need for medication) and developing a treatment plan.

F386, Physician Visits — Determine whether the physician or her/his designee:

- Reviewed the resident's total program of care including medications,
- Wrote relevant progress notes at each visit required,
- Assessed for underlying causative factors,
- Established a treatment regimen which considered non-pharmacological interventions as well as medication; and
- Reviewed the medication regimen for potential unnecessary medications and the effectiveness as well as potential complications of the regimen.

F428, Drug Regimen Review — Determine whether the licensed pharmacist has:

- Performed a review at least monthly (or more frequently if the resident has had frequent changes in the medication regimen or at least initially for short stay residents);
- Identified actual or potential MRPs;
- Provided a report to the DON and attending physician;
 - That the attending physician and facility have acted upon these reports; and

Stage II – Critical Elements for Psychoactive Medications

Concerns with Structure, Process, and/or Outcome Requirements Related to Process of Care

- The facility has retained these reports and incorporated the reports into the clinical record.

F501, Medical Director — Determine whether the medical director:

- Has been involved in the coordination of medical care, which includes, in collaboration with the facility, the development of policies and procedures regarding the provision of care and services for residents who receive psychoactive medications and
- Whether the medical director was involved in the evaluation of medication irregularities that are identified or reported, and has been working with the facility and practitioners to take appropriate action.

If the surveyor determines that the facility is not in compliance with any of these related requirements, the appropriate F tag should be surveyor initiated.